Atrium spun out of Avidity Biosciences, which Novartis acquired in a $12 billion deal. The Atrium pipeline is led by two RNA therapies with a path to the clinic for rare inherited cardiological disorders that have no FDA-approved drugs.
The post Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions appeared first on MedCity News.
Ship tracking reveals tankers and millions of barrels of oil stuck in the Gulf
Sky’s Data and Forensics team has been monitoring shipping through the Strait of Hormuz – a strategically vital waterway for Iran and other oil producers
